Customer Letters

Please note: The following Customer Letters, do not replace the version that you receive from your local Canadian Blood Services site.

* The contents of the customer letters available on this site are current as of their dates of publication. If required, contact your local Hospital Liaison Specialist to determine if the letter is still current.

Displaying 1 - 33 of 33

	Date Sort ascending
CL_2023-33.pdf	2023-11-21	INFORMATION ONLY Manufacturing Changes for Cytogam Customer Letter 2023-33 (PDF) \| Cytogam Product Monograph (PDF) \| Cytogam Customer Letter (PDF)
CL_2023-32.pdf	2023-11-14	INFORMATION ONLY Packaging Change for WinRho 1500IU Customer Letter 2023-32 (PDF) \| WinRho Product Monograph (PDF) \| WinRho Customer Letter (PDF)
CL_2023-31.pdf	2023-11-01	INFORMATION ONLY Introduction of Glassia Customer Letter 2023-31 (PDF)
CL_2023-30.pdf	2023-10-31	INFORMATION ONLY Health Canada Letter on Mixing of Red Blood Cells with Solvent Detergent Plasma Customer Letter 2023-30 (PDF) \| Health Canada letter (PDF)
CL_2023-29.pdf	2023-10-30	INFORMATION ONLY New Tamper Indication Device Trial Customer Letter 2023-29 (PDF)
CL_2023-28.pdf	2023-10-30	ACTION REQUIRED Update on Panzyga, Cutaquig and Octagam Availability Customer Letter 2023-28 (PDF)
CL_2023-27.pdf	2023-10-16	INFORMATION ONLY Introduction of HyQvia Customer Letter 2023-27 (PDF) \| Introducing HyQvia^MD in Canada (PDF)
CL_2023-26.pdf	2023-09-29	INFORMATION ONLY Additional Information for Thawing Octaplasma Customer Letter 2023-26 (PDF) \| Thawing of Octaplasma Additional Information (PDF)
CL_2023-25.pdf	2023-09-28	INFORMATION ONLY Fibryga – Notice of Shelf-Life Extension to 48 Months (Revision) Customer Letter 2023-25 (PDF) \| Fibryga^® Shelf-Life Extension – Revised Letter (PDF)
CL_2023-24.pdf	2023-09-06	ACTION REQUIRED FEIBA Defect – Particles in BAXJECT II HF Device Customer Letter 2023-24 (PDF) \| Takeda Customer Letter (PDF)
CL_2023-23.pdf	2023-09-05	INFORMATION ONLY Update to Special Request Order Form Customer Letter 2023-23 (PDF)
CL_2023-22.pdf	2023-08-30	INFORMATION ONLY Changes to Rad-Sure Irradiation Indicator Labels Customer Letter 2023-22 (PDF)
CL_2023-21.pdf	2023-08-14	INFORMATION ONLY Substituting Frozen Plasma Customer Letter 2023-21 (PDF)
CL_2023-20.pdf	2023-08-14	INFORMATION ONLY Update On Expanded Use of Solvent Detergent Plasma Customer Letter 2023-20 (PDF)
CL_2023-19.pdf	2023-08-04	INFORMATION ONLY Fibryga – Notice of Shelf-Life Extension to 48 Months Customer Letter 2023-19 (PDF) \| Fibryga® Shelf-Life Extension (PDF)
CL_2023-18.pdf	2023-07-12	INFORMATION ONLY Revision of Request for RHD Genotyping Form Customer Letter 2023-18 (PDF)
CL_2023-17.pdf	2023-07-10	ACTION REQUIRED National Deployment of Pathogen-Reduced Platelets: Fifth Update  Customer Letter 2023-17 (PDF)
CL_2023-16.pdf	2023-07-10	INFORMATION ONLY New Manual Contingency Process for Release Labelling Customer Letter 2023-16 (PDF)
CL_2023-15.pdf	2023-06-21	INFORMATION ONLY Panzyga, Octagam and Cutaquig Unavailable for Exceptional Access Cases Customer Letter 2023-15 (PDF)
CL_2023-14.pdf	2023-06-16	INFORMATION ONLY Cytogam Shortage – Temporary Supply of US-labelled Cytogam Customer Letter 2023-14 (PDF) \| Important Information on Cytogam Shortage - Temporary Supply of US-labelled Cytogam (PDF)
CL_2023-13.pdf	2023-06-05	ACTION REQUIRED Health Canada Approved - Apheresis Platelets Psoralen-treated and Apheresis Platelets PAS-E Added Customer Letter 2023-13 (PDF)
CL_2023-12.pdf	2023-05-16	ACTION REQUIRED National Deployment of Pathogen-Reduced Platelets: Fourth Update Customer Letter 2023-12 (PDF)
CL_2023-11.pdf	2023-04-27	INFORMATION ONLY FAQ for the Request for Proposals (RFP) for Immunoglobulins and other Plasma Protein and Related Products (PPRP) Customer Letter 2023-11 (PDF) \| 2023 IVIg Transition FAQ (PDF)
CL_2023-10.pdf	2023-04-14	ACTION REQUIRED Shelf Life Extension of Pooled Platelets Psoralen-Treated Components from 5 to 7 Days Customer Letter 2023-10 (PDF)
CL_2023-09.pdf	2023-04-03	ACTION REQUIRED National Deployment of Pathogen-Reduced Platelets: Third Update Customer Letter 2023-09 (PDF)
CL_2023-08.pdf	2023-03-24	INFORMATION ONLY Alprolix and Eloctate Packaging Changes Customer Letter 2023-08 (PDF) \| ALPROLIX Hemophilia B Enrolment Form (PDF) \| ELOCTATE Hemophilia A Enrolment Form (PDF) \| ALPROLIX - ELOCTATE Notification Letter (PDF)
CL_2023-07.pdf	2023-03-23	INFORMATION ONLY NAC Recommendations for the Use of Solvent-Detergent Plasma in Canada; Important Changes to Post Thaw Storage of Octaplasma Customer Letter 2023-07 (PDF) \| Octaplasma^®Advisory Letter (PDF)
CL_2023-06.pdf	2023-03-20	INFORMATION ONLY Vonvendi^® - Interim Plasma Protein and Related Products Review Decision Customer Letter 2023-06 (PDF)
CL_2023-05.pdf	2023-03-13	ACTION REQUIRED Information on Immunoglobulin Inventory Following Results of the Request for Proposals (RFP) for Plasma-Derived Plasma Protein and Related Products (PPRP) Customer Letter 2023-05 (PDF)
CL_2023-04.pdf	2023-02-07	INFORMATION ONLY Further Information on Expanded Use of Solvent Detergent Plasma: Education Materials and Ordering Information Customer Letter 2023-04 (PDF) \| Octaplasma^®Customer Letter (PDF) \| Octaplasma^® - Q&A for Transfusion Medicine Laboratory (PDF)
CL_2023-03.pdf	2023-02-06	ACTION REQUIRED National Deployment of Pathogen-Reduced Platelets: Second Update Customer Letter 2023-03 (PDF)
CL_2023-02.pdf	2023-01-27	INFORMATION ONLY Update to Label Changes for Rare International Red Blood Cells Customer Letter 2023-02 (PDF) \| Attachment 1 (PDF)
CL_2023-01.pdf	2023-01-10	INFORMATION ONLY Further Information on Expanded Use of Solvent Detergent Plasma: Updated Post Thaw Expiration, Sample Labels and Implementation Checklist Customer Letter 2023-01 (PDF) \| Recommended Solvent Detergent Plasma Hospital Implementation Checklist (PDF) \| Octaplasma: Blood Bank Communication (PDF) \| Octaplasma B Label Mockup (PDF) \| Octaplasma A Label Mockup (PDF) \| Octaplasma AB Label Mockup (PDF) \| Octaplasma O Label Mockup (PDF)